Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Polygenic Pharmacogenomic Markers as Predictors of Toxicity Phenotypes in the Treatment of Acute Lymphoblastic Leukemia: A Single-Center Study.

JCO precision oncology - 1 Mar 2023

Larkin Trisha, Kashif Reema, Elsayed Abdelrahman H, Greer Beate, Mangrola Karna, Rafiee Roya, Nguyen Nam, Shastri Vivek, Horn Biljana, Lamba Jatinder K

Abstract excerpt

PURPOSE: Acute lymphoblastic leukemia (ALL) is the most prevalent cause of childhood cancer and requires a long course of therapy consisting of three primary phases with interval intensification blocks. Although these phases are necessary to achieve remission, the primary chemotherapeutic agents have potentially serious toxicities, which may lead to delays or discontinuations of therapy. The purpose of this study...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cross-Sectional Studies

Share to Genomics and Rare Diseases

Share to Pharmacogenetics

Share to Pharmacogenetics and Drug Metabolism

Share to Phenotype

Share to Precursor Cell Lymphoblastic Leukemia-Lymphoma

Source

Open in PubMed Open full text

Identifiers

PMID: 36952646
DOI: 10.1200/PO.22.00580
PMCID: PMC10309546

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Polygenic Pharmacogenomic Markers as Predictors of Toxicity Phenotypes in the Treatment of Acute Lymphoblastic Leukemia: A Single-Center Study.PMID 36952646Read ↗

Implementation of Pharmacogenetics to Individualize Treatment Regimens for Children with Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

Polygenic risk score-assessment of drug induced hepatotoxicity in high-risk acute lymphoblastic leukemiaSemantic proximity Read ↗

Pharmacogenetic Predictors of Treatment-Related Toxicity Among Children With Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

Genetic basis of clinical variants of chemotherapy toxicity in children with acute lymphoblastic leukemia (literature review)Semantic proximity Read ↗

Pharmacogenetic considerations for acute lymphoblastic leukemia therapies.Semantic proximity Read ↗

The Promise of Pharmacogenomics in Reducing Toxicity during Acute Lymphoblastic Leukemia Maintenance TreatmentSemantic proximity Read ↗

Pharmacogenetics in acute lymphoblastic leukemia.Semantic proximity Read ↗

Leveraging Genome and Phenome-Wide Association Studies to Investigate Genetic Risk of Acute Lymphoblastic Leukemia.Semantic proximity Read ↗

Chemotherapy-related hyperbilirubinemia in pediatric acute lymphoblastic leukemia: a genome-wide association study from the AIEOP-BFM ALL Study GroupSemantic proximity Read ↗

Approaches to the discovery of pharmacogenomic markers in oncology: 2000-2010-2020.Semantic proximity Read ↗

Treatment-related toxicities in children with acute lymphoblastic leukaemia predisposition syndromes.Semantic proximity Read ↗

Acute central nervous system toxicity during treatment of pediatric acute lymphoblastic leukemia: phenotypes, risk factors and genotypes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.